These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 20063546

  • 1. A new chemoimmunotherapy regimen (OXAFI) for advanced hepatocellular carcinoma.
    Ang MK, Poon D, Foo KF, Chung YF, Chow P, Wan WK, Thng CH, Ooi L.
    Hematol Oncol Stem Cell Ther; 2008; 1(3):159-65. PubMed ID: 20063546
    [Abstract] [Full Text] [Related]

  • 2. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma.
    Leung TW, Patt YZ, Lau WY, Ho SK, Yu SC, Chan AT, Mok TS, Yeo W, Liew CT, Leung NW, Tang AM, Johnson PJ.
    Clin Cancer Res; 1999 Jul; 5(7):1676-81. PubMed ID: 10430068
    [Abstract] [Full Text] [Related]

  • 3. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.
    Patt YZ, Hassan MM, Lozano RD, Brown TD, Vauthey JN, Curley SA, Ellis LM.
    J Clin Oncol; 2003 Feb 01; 21(3):421-7. PubMed ID: 12560429
    [Abstract] [Full Text] [Related]

  • 4. Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma.
    Yin XY, Lü MD, Liang LJ, Lai JM, Li DM, Kuang M.
    World J Gastroenterol; 2005 Apr 28; 11(16):2526-9. PubMed ID: 15832431
    [Abstract] [Full Text] [Related]

  • 5. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
    Leung TW, Tang AM, Zee B, Yu SC, Lai PB, Lau WY, Johnson PJ.
    Cancer; 2002 Jan 15; 94(2):421-7. PubMed ID: 11905412
    [Abstract] [Full Text] [Related]

  • 6. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
    Lu YS, Hsu C, Li CC, Kuo SH, Yeh KH, Yang CH, Hsu CH, Wu CY, Cheng AL.
    Hepatogastroenterology; 2004 Jan 15; 51(57):815-9. PubMed ID: 15143923
    [Abstract] [Full Text] [Related]

  • 7. Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma.
    Kaseb AO, Shindoh J, Patt YZ, Roses RE, Zimmitti G, Lozano RD, Hassan MM, Hassabo HM, Curley SA, Aloia TA, Abbruzzese JL, Vauthey JN.
    Cancer; 2013 Sep 15; 119(18):3334-42. PubMed ID: 23821538
    [Abstract] [Full Text] [Related]

  • 8. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.
    Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A, Johnson PJ.
    J Natl Cancer Inst; 2005 Oct 19; 97(20):1532-8. PubMed ID: 16234567
    [Abstract] [Full Text] [Related]

  • 9. Hepatic intra-arterial interferon alpha 2b-based immunotherapy combined with 5-fluorouracil (5-FU)-based systemic chemotherapy for patients with hepatocellular carcinoma (HCC) not responsive and/or not eligible for conventional treatments: a pilot study.
    Vitale FV, Romeo P, Vasta F, Panebianco V, Calì S, Rotondo S, Ferraù F, La Greca M.
    Anticancer Res; 2007 Oct 19; 27(6B):4077-81. PubMed ID: 18225574
    [Abstract] [Full Text] [Related]

  • 10. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.
    Lee J, Park JO, Kim WS, Park SH, Park KW, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Joh J, Kim K, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Park K.
    Cancer Chemother Pharmacol; 2004 Nov 19; 54(5):385-90. PubMed ID: 15248028
    [Abstract] [Full Text] [Related]

  • 11. A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma.
    Uhm JE, Park JO, Lee J, Park YS, Park SH, Yoo BC, Paik SW, Koh KC, Kang WK, Lim HY.
    Cancer Chemother Pharmacol; 2009 Apr 19; 63(5):929-35. PubMed ID: 18726098
    [Abstract] [Full Text] [Related]

  • 12. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, Lee JH, Sun Y.
    J Clin Oncol; 2013 Oct 01; 31(28):3501-8. PubMed ID: 23980077
    [Abstract] [Full Text] [Related]

  • 13. Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma.
    Kuroda M, Kobayashi Y, Urawa N, Yamamoto M, Mifuji R, Araki J, Tanaka H, Horiike S, Itani T, Furjita N, Konishi M, Iwasa M, Kaito M, Adachi Y.
    Hepatogastroenterology; 2007 Mar 01; 54(74):518-21. PubMed ID: 17523311
    [Abstract] [Full Text] [Related]

  • 14. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma.
    Lau WY, Leung TW, Lai BS, Liew CT, Ho SK, Yu SC, Tang AM.
    Ann Surg; 2001 Feb 01; 233(2):236-41. PubMed ID: 11176130
    [Abstract] [Full Text] [Related]

  • 15. Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis.
    He MK, Zou RH, Li QJ, Zhou ZG, Shen JX, Zhang YF, Yu ZS, Xu L, Shi M.
    Cardiovasc Intervent Radiol; 2018 May 01; 41(5):734-743. PubMed ID: 29327075
    [Abstract] [Full Text] [Related]

  • 16. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
    Ilson DH, Sirott M, Saltz L, Heelan R, Huang Y, Keresztes R, Kelsen DP.
    Cancer; 1995 May 01; 75(9):2197-202. PubMed ID: 7712428
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion.
    Kasai K, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, Kuroda H, Takikawa Y, Suzuki K.
    Cancer; 2012 Jul 01; 118(13):3302-10. PubMed ID: 22072099
    [Abstract] [Full Text] [Related]

  • 18. Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma.
    Kardinal CG, Moertel CG, Wieand HS, Schutt AJ, O'Connell MJ, Wright K, Wiesenfeld M, Tschetter LK, Krook JE.
    Cancer; 1993 Apr 01; 71(7):2187-90. PubMed ID: 8384064
    [Abstract] [Full Text] [Related]

  • 19. Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: a report from the Childrens Cancer Study Group.
    Ortega JA, Krailo MD, Haas JE, King DR, Ablin AR, Quinn JJ, Feusner J, Campbell JR, Lloyd DA, Cherlow J.
    J Clin Oncol; 1991 Dec 01; 9(12):2167-76. PubMed ID: 1720452
    [Abstract] [Full Text] [Related]

  • 20. A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma.
    Lee DW, Lee KH, Kim HJ, Kim TY, Kim JS, Han SW, Oh DY, Kim JH, Im SA, Kim TY.
    BMC Cancer; 2018 Mar 05; 18(1):252. PubMed ID: 29506478
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.